Advice

Following a re-submission:

abiraterone acetate (Zytiga®) is accepted for restricted use within NHS Scotland.

Indication under review: with prednisone or prednisolone for the treatment of metastatic castration resistant prostate cancer (mCRPC) in adult men whose disease has progressed on or after a docetaxel-based chemotherapy regimen.

SMC restriction: abiraterone is restricted to use in patients who have received only one prior chemotherapy regimen.

Abiraterone plus prednisone was associated with significantly improved overall survival compared with placebo plus prednisone in patients with mCRPC previously treated with docetaxel.

This SMC advice takes account of the benefits of a Patient Access Scheme (PAS) that improves the cost-effectiveness of abiraterone. This SMC advice is contingent upon the continuing availability of the patient access scheme in NHS Scotland.

Download detailed advice166KB (PDF)

Download

Medicine details

Medicine name:
abiraterone (Zytiga)
SMC ID:
764/12
Indication:
With prednisone or prednisolone for the treatment of metastatic castration resistant prostate cancer (mCRPC) in adult men whose disease has progressed on or after a docetaxel-based chemotherapy regimen.
Pharmaceutical company
Janssen-Cilag Ltd
BNF chapter
Malignant disease and immunosuppression
Submission type
Resubmission
Status
Restricted
Date advice published:
13 August 2012